ABP 301
Alternative Names: ABP-301; ABP-C19-01Latest Information Update: 29 Apr 2021
At a glance
- Originator Abpro Therapeutics
- Class Antibodies; Antivirals
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical COVID 2019 infections
Most Recent Events
- 31 Mar 2021 Preclinical trials in COVID-2019 infections in USA (Parenteral), prior to March 2021 (Abpro Therapeutics pipeline, March 2021)